Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COYA Coya Therapeutics	$5.76 -6.2%	$6.10	$4.65 ▼ $10.24	$96.34M	0.49	73,208 shs	106,506 shs
GBIO Generation Bio	$0.39 +0.6%	$0.43	$0.32 ▼ $4.34	$26.32M	2.76	299,949 shs	308,751 shs
IVVD Invivyd	$0.86 +2.8%	$0.64	$0.35 ▼ $2.74	$103.27M	0.4	4.40 million shs	7.32 million shs
SGMT Sagimet Biosciences	$3.18 -3.9%	$3.08	$1.73 ▼ $7.38	$97.55M	2.32	859,845 shs	504,189 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COYA Coya Therapeutics	-1.44%	-4.21%	+18.76%	-7.39%	-25.21%
GBIO Generation Bio	+11.23%	-4.48%	+0.10%	-38.03%	-86.94%
IVVD Invivyd	+31.11%	+45.60%	+52.60%	-50.13%	-62.93%
SGMT Sagimet Biosciences	+2.16%	-7.80%	+43.29%	-29.87%	-25.45%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COYA Coya Therapeutics	2.3946 of 5 stars	3.5	5.0	2.0	0.8	0.0
GBIO Generation Bio	3.6402 of 5 stars	3.5	5.0	1.8	3.3	1.3
IVVD Invivyd	3.0861 of 5 stars	3.6	2.0	2.1	3.3	1.3
SGMT Sagimet Biosciences	2.8489 of 5 stars	3.4	2.0	4.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COYA Coya Therapeutics	3.00	Buy	$17.00	195.14% Upside
GBIO Generation Bio	3.00	Buy	$7.33	1,767.41% Upside
IVVD Invivyd	3.25	Buy	$7.52	773.12% Upside
SGMT Sagimet Biosciences	2.80	Moderate Buy	$22.40	604.40% Upside

Current Analyst Ratings Breakdown

Latest GBIO, COYA, SGMT, and IVVD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/13/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
5/8/2025	GBIO Generation Bio	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
4/28/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/22/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
4/10/2025	GBIO Generation Bio	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
3/27/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
3/26/2025	IVVD Invivyd	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/20/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
3/20/2025	IVVD Invivyd	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
3/18/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
3/17/2025	GBIO Generation Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00

(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COYA Coya Therapeutics	$3.55M	27.11	N/A	N/A	$2.47 per share	2.33
GBIO Generation Bio	$19.89M	1.32	N/A	N/A	$3.07 per share	0.13
IVVD Invivyd	$25.38M	4.07	N/A	N/A	$1.61 per share	0.53
SGMT Sagimet Biosciences	$2M	48.77	N/A	N/A	$3.98 per share	0.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COYA Coya Therapeutics	-$7.99M	-$0.98	N/A	N/A	N/A	N/A	-31.63%	-27.76%	N/A
GBIO Generation Bio	-$126.61M	-$1.08	N/A	N/A	N/A	-782.86%	-104.85%	-49.54%	N/A
IVVD Invivyd	-$198.64M	-$1.44	N/A	7.83	N/A	N/A	-155.33%	-114.88%	5/15/2025 (Estimated)
SGMT Sagimet Biosciences	-$27.88M	-$1.43	N/A	N/A	N/A	N/A	-23.63%	-22.91%	5/21/2025 (Estimated)

Latest GBIO, COYA, SGMT, and IVVD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	SGMT Sagimet Biosciences	-$0.79	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	IVVD Invivyd	-$0.04	N/A	N/A	N/A	$34.45 million	N/A
5/8/2025	Q1 2025	SGMT Sagimet Biosciences	-$0.79	-$0.56	+$0.23	-$0.56	N/A	N/A
5/7/2025	Q1 2025	GBIO Generation Bio	-$0.25	-$0.22	+$0.03	-$0.22	$1.70 million	$8.72 million
3/20/2025	Q4 2024	IVVD Invivyd	-$0.25	-$0.15	+$0.10	-$0.15	$13.57 million	$13.80 million
3/19/2025	Q4 2024	GBIO Generation Bio	-$0.31	-$0.32	-$0.01	-$0.32	$2.92 million	$4.19 million
3/18/2025	Q4 2024	COYA Coya Therapeutics	-$0.32	-$0.18	+$0.14	-$0.18	$0.10 million	$0.20 million
3/12/2025	Q4 2024	SGMT Sagimet Biosciences	-$0.65	-$0.50	+$0.15	-$0.50	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COYA Coya Therapeutics	N/A	N/A	N/A	N/A	N/A
GBIO Generation Bio	N/A	N/A	N/A	N/A	N/A
IVVD Invivyd	N/A	N/A	N/A	N/A	N/A
SGMT Sagimet Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COYA Coya Therapeutics	N/A	15.31	15.31
GBIO Generation Bio	N/A	6.34	6.34
IVVD Invivyd	N/A	1.92	1.58
SGMT Sagimet Biosciences	N/A	38.41	38.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COYA Coya Therapeutics	39.75%
GBIO Generation Bio	95.22%
IVVD Invivyd	70.36%
SGMT Sagimet Biosciences	87.86%

Insider Ownership

Company	Insider Ownership
COYA Coya Therapeutics	12.00%
GBIO Generation Bio	21.80%
IVVD Invivyd	25.40%
SGMT Sagimet Biosciences	17.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COYA Coya Therapeutics	6	16.73 million	14.70 million	Not Optionable
GBIO Generation Bio	150	67.01 million	52.70 million	Optionable
IVVD Invivyd	100	119.96 million	98.21 million	Optionable
SGMT Sagimet Biosciences	8	30.68 million	25.28 million	Optionable

GBIO, COYA, SGMT, and IVVD Headlines

Recent News About These Companies

Sagimet Biosciences Inc. (NASDAQ:SGMT) Shares Purchased by Bridgeway Capital Management LLC

May 13 at 5:24 AM | marketbeat.com

Sagimet Biosciences (SGMT) & Its Rivals Critical Analysis

May 11 at 2:08 AM | americanbankingnews.com

Renaissance Technologies LLC Sells 220,300 Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT)

May 10 at 3:20 AM | marketbeat.com

Sagimet Biosciences Inc.: Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 9, 2025 | finanznachrichten.de

Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 8, 2025 | globenewswire.com

Sagimet Biosciences Inc. (NASDAQ:SGMT) Shares Sold by Alyeska Investment Group L.P.

May 8, 2025 | marketbeat.com

Boothbay Fund Management LLC Has $56,000 Stock Holdings in Sagimet Biosciences Inc. (NASDAQ:SGMT)

May 7, 2025 | marketbeat.com

Sagimet Biosciences Inc. (NASDAQ:SGMT) Shares Sold by Baker BROS. Advisors LP

May 6, 2025 | marketbeat.com

138,263 Shares in Sagimet Biosciences Inc. (NASDAQ:SGMT) Bought by 683 Capital Management LLC

May 4, 2025 | marketbeat.com

Blue Owl Capital Holdings LP Has $5.96 Million Stake in Sagimet Biosciences Inc. (NASDAQ:SGMT)

April 26, 2025 | marketbeat.com

Sagimet Biosciences announces presentations at EASL Congress 2025

April 25, 2025 | markets.businessinsider.com

Sagimet Biosciences to Present Phase 2b FASCINATE-2 Study Findings on Denifanstat at EASL Congress 2025

April 23, 2025 | quiverquant.com

Why Sagimet Biosciences Inc.’s (SGMT) Stock Is Up 7.11%

April 23, 2025 | aaii.com

Sagimet Biosciences Announces Upcoming Presentations at EASL Congress 2025

April 23, 2025 | finance.yahoo.com

Why Sagimet Biosciences Inc.’s (SGMT) Stock Is Down 14.92%

April 7, 2025 | aaii.com

Why Sagimet Biosciences Inc.’s (SGMT) Stock Is Down 12.37%

March 31, 2025 | aaii.com

Sagimet Biosciences Gets Clearance To Initiate Phase 1 Study Of TVB-3567 For Treatment Of Acne

March 13, 2025 | nasdaq.com

Sagimet Biosciences Inc.: Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne

March 12, 2025 | finanznachrichten.de

Sagimet Biosciences reports Q4 EPS (50c), consensus (63c)

March 12, 2025 | markets.businessinsider.com

Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates

March 12, 2025 | globenewswire.com

Sagimet Biosciences announces clearance of IND for FASN inhibitor TVB-3567

March 11, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GBIO, COYA, SGMT, and IVVD Company Descriptions

Coya Therapeutics NASDAQ:COYA

$5.76 -0.38 (-6.19%)

As of 04:00 PM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Generation Bio NASDAQ:GBIO

$0.39 +0.00 (+0.59%)

As of 04:00 PM Eastern

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Invivyd NASDAQ:IVVD

$0.86 +0.02 (+2.76%)

As of 04:00 PM Eastern

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

Sagimet Biosciences NASDAQ:SGMT

$3.18 -0.13 (-3.93%)

As of 04:00 PM Eastern

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time